// App-Quantinova.ai

e18321 : Budget impact model (BIM) to evaluate treatment costs associated with variable utilization rates of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Edward Joseph Drea

Principal Investigators

  • Shelby Corman

  • Alex R Cockerham

  • Miraj Patel

  • Louis Hudspeth

  • Andrew Kenneth Yu

Medical Centers

  • Sanofi, Bridgewater, NJ

  • Pharmerit International, Bethesda, MD

  • Group Health Cooperative, Lacey, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • BCL2 like 11

Drug/Treatment

  • CB-7598

  • Enzalutamide

  • Cabazitaxel

  • Radium-223 Dichloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved